<DOC>
	<DOC>NCT01417676</DOC>
	<brief_summary>This is a prospective, open label 1 arm study, multicentre, Phase I/II clinical safety study. The trial is designed to gain initial safety and efficacy data on pelvic lymph node radiation with simultaneous integrated boost to prostate in high risk prostate cancer patients.</brief_summary>
	<brief_title>DAPROCA Pelvic Lymph Node Irradiation to Prostate for High Risk Prostate Cancer: Phase I/II Study</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>adenocarcinoma T3 tumor and either Gleason 810 and PSA ≤ 70,or PSA ≥ 30 and PSA ≤ 70, or T1T3 and PSA ≤ 70 and N1 no distant metastases pelvic comorbidity such as Crohns disease or ulcerative colitis uncontrolled heart or lung morbidity prior radiation treatment of pelvic region age &gt; 75 years</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>locally advanced</keyword>
	<keyword>lymph node positive</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>morbidity</keyword>
	<keyword>early morbidity</keyword>
	<keyword>late morbidity</keyword>
</DOC>